GlassScriptPhysician profile
Laura R Driggers
NPI 1952757825
$954.41
in general payments reported to CMS, 2019-2025
21 companies · $10.93 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $432 · 2023: $383 · 2025: $10.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $151.76 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $109.57 | 2022-2023 | Emgality, Jardiance, Mounjaro |
| Abbvie INC. | $102.31 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.93 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $76.91 | 2022-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $57.33 | 2022-2023 | Seglentis, Livalo |
| Abbott Laboratories | $56.21 | 2023 | Freestyle Libre |
| Biohaven Pharmaceutical Holding Company LTD. | $49.05 | 2022 | |
| Merck Sharp & Dohme LLC | $41.59 | 2021-2023 | Steglujan, Steglatro, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $38.30 | 2022 | |
| Dexcom, INC. | $31.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.65 | 2021 | |
| Pfizer INC. | $18.70 | 2023 | |
| Supernus Pharmaceuticals, INC. | $17.05 | 2022 | |
| Amgen INC. | $15.87 | 2023 | Otezla, Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.59 | 2023 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.45 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $15.44 | 2023 | Quviviq |
| Kerecis Limited | $10.93 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sunovion Pharmaceuticals INC. | $10.86 | 2021 | |
| Genentech USA, INC. | $10.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Driggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.